AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Study sponsor: Amylyx Pharmaceuticals Inc. · AMLX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-09-25Actual
Enrollment · participants137Actual
Source updated2024-05-16Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.